Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
All articles
Showing 145–156 of 411 articles
- Interpret the evidence
What the 2026 Compounding Policy Does and Does Not Say About GLOW
GLOW is a catalog blend name, which in the formulation discussed here refers to GHK-Cu, BPC-157 and TB-500. Some of those names also appear in federal documents. Seeing a name in a policy does not establish that a commercial blend has been evaluated.
GLOW Blend2 sources (2026)
- Check methods and identity
Why Adding MOTS c Changes the Question Behind the GLOW 2 Label
GLOW 2 is a catalog name for a mixture. The formulation described in the supplied catalog names GHK-Cu, BPC-157 and MOTS-c, although the exact supplier formulation is unconfirmed. This account uses those names to discuss the research questions they raise.
GLOW 2 Blend2 sources (2026)
- Explore study findings
What a Mouse Mitochondria Study Can Explain About One GLOW 2 Ingredient
GLOW 2, as described in the catalog, includes a material named MOTS-c alongside GHK-Cu and BPC-157. The exact blend formulation remains unconfirmed.
GLOW 2 Blend1 source (2026)
- Interpret the evidence
Why a Human Muscle Cell Study Is Not a GLOW 2 Clinical Trial
MOTS-c is a mitochondrial peptide named as one component of the catalog's GLOW 2 formulation. In 2026, Rabie Elhusseiny and colleagues tested MOTS-c in human-derived muscle cells exposed to dexamethasone, a glucocorticoid. The researchers studied one ingredient in a cell model.
GLOW 2 Blend1 source (2026)
- Check methods and identity
What Measuring Naturally Occurring MOTS c Can Tell Us
MOTS-c is a mitochondrial peptide named in the catalog description of GLOW 2. Studying naturally occurring MOTS-c in people's blood or tissue asks a different question from studying a mixture given to a person. A 2026 study of polycystic ovary syndrome illustrates the difference.
GLOW 2 Blend1 source (2026)
- Check methods and identity
Why Oxygen Measurements in Wounds Differ From Muscle Energy Measurements
GLOW 2 is a catalog blend name linked to GHK-Cu, BPC-157 and MOTS-c. Research on two of those names sometimes uses similar words, such as oxygen, oxidative stress or energy. A closer look at the experiments shows that those words refer to different measurements.
GLOW 2 Blend2 sources (2026)
- Explore study findings
What the 2026 MOTS c Appraisal Means for Claims About GLOW 2
The GLOW 2 formulation described in the catalog names the mitochondrial peptide MOTS-c together with GHK-Cu and BPC-157. The exact preparation has not been confirmed. Federal documents that discuss MOTS-c provide useful context for assessing what is known about that ingredient.
GLOW 2 Blend2 sources (2026)
- Explore study findings
What three semaglutide trials tell us about kidney outcomes
Semaglutide is a modified peptide that activates the glucagon-like peptide-1, or GLP-1, receptor. It is used in several approved formulations for specific conditions.
GLP-1 SEMA2 sources (2026)
- Check methods and identity
Why an alcohol study measured craving and drinking separately
Semaglutide is a GLP-1 receptor agonist with approved uses for specified metabolic and cardiovascular indications, depending on the product. In a 2026 trial, researchers investigated a different question.
GLP-1 SEMA2 sources (2026)
- Interpret the evidence
How researchers compared semaglutide tablets and injections across trials
Semaglutide is a modified peptide that activates the GLP-1 receptor. It is available in FDA-approved oral and injectable products with product-specific indications.
GLP-1 SEMA2 sources (2026)
- Explore study findings
What BARI-STEP found after bariatric surgery
Semaglutide is a modified GLP-1 receptor agonist peptide. In the 2026 BARI-STEP trial, researchers tested whether it affected body weight in adults who had lost less weight than the study’s threshold after bariatric surgery.
GLP-1 SEMA2 sources (2026)
- Explore study findings
What two Alzheimer’s trials found about oral semaglutide
Semaglutide is a modified GLP-1 receptor agonist. Researchers investigated whether its oral form could slow progression in people with early symptomatic Alzheimer’s disease. Two phase 3 trials reported in 2026 compared it with placebo.
GLP-1 SEMA2 sources (2026)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
